Abbott opens new pharma research lab in Singapore
Abbott is has opened a new pharmaceutical analytical research laboratory in Singapore's Biopolis research park.
Abbott is has opened a new pharmaceutical analytical research laboratory in Singapore's Biopolis research park.
The new facility, Abbott's first pharma r&d site in southeast Asia, will conduct stability studies, including studies on active pharmaceutical ingredients and novel formulations, to support global regulatory requirements for new pharmaceutical products. The work done at the laboratory will enable Abbott to accelerate the development of innovative investigational medicines and potentially deliver new treatments to patients faster in areas such as neuroscience and cancer.
"Abbott has continually increased its investment in r&d over the last decade, resulting in a promising pipeline," said Dr John M. Leonard, senior vice president, pharmaceuticals, research and development. "To realise the potential from the growth in Abbott's early stage pipeline requires the resources of a truly global r&d organisation and the scientific talent available in Singapore made it a logical choice for Abbott's expansion in the region."
Abbott has expanded its presence in Singapore over the last few years with the launch of several key products, including Humira and the Xience V drug-eluting stent. Singapore is also home to regional headquarters offices for several Abbott businesses including nutrition, pharmaceuticals and diagnostics.
The Singapore laboratory is Abbott's latest global investment in facilities and resources to advance its pipeline. These initiatives include the Formulation Development Center that opened in Abbott Park, Illinois, US, in June last year and expansions at Abbott's drug delivery operations, SOLIQS, announced in Ludwigshafen, Germany, in October 2008.
